Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | HTR3A | P46098 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30656303 | 1.00 | ADRB1 (0.62) | ADRB1ADRA2CALDH1A1HPGDSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL28721086 | 0.98 | ADRB1 (0.60) | ADRB1ADRA2CALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15061993 | 0.92 | NCF1 (0.61) | ADRB1ADRA2CALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4291189 | 0.91 | ADRB1 (0.72) | ADRB1ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL7583950 | 0.89 | ADRB1 (0.51) | ADRB1ADRA2CALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13243993 | 0.83 | ADRB1 (0.65) | ADRB1ADRA2CALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL286304 | 0.82 | SLC18A3 (0.56) | ADRB1ADRA2CALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL10118836 | 0.82 | ADRB1 (0.61) | ADRB1ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL329301 | 0.82 | ADRB1 (0.67) | ADRB1ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL27961590 | 0.82 | ADRB1 (0.67) | ADRB1ALDH1A1HPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20220411383-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20040224993-A1 | Diphenylurea compounds | LAVIELLE GILBERT (FR) | 2004-11-11 | — | — | US | disclosed |
| US-6784183-B2 | ANTISEROTONINE AGENTS | LES LABORATOIRES SERVIER (FR) | 2004-08-31 | — | — | US | disclosed |
| EP-1170288-B1 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | SERVIER LAB (FR) | 2004-08-11 | — | — | EP | disclosed |
| WO-2004013141-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | WO | disclosed |
| US-20020025965-A1 | Antiserotonine agents | ADIR ET COMPAGNIE (FR) | 2002-02-28 | — | — | US | disclosed |
| EP-1170288-A2 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
| US-4775757-A | CARDIOTONIC AND RENAL VASODILATING AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-10-04 | — | — | US | disclosed |
| US-4078066-A | HYPOTENSIVE AGENTS, SURFACTANTS, BACTERICIDES AND WATER SOFTENERS | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4033971-A | HYPOTENSIVES, SURFACTANTS, BACTERICIDES, WATER SOFTENERS | E. R. SQUIBB & SONS, INC. (US) | 1977-07-05 | — | — | US | disclosed |
| US-3936465-A | SURFACTANT, WATER SOFTENER, BACTERICIDE, HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | NOTCH1, NOTCH2, NOTCH4 | ADRB1 4782/4885ADRA2C 4882/4885ALDH1A1 2288/4885 |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | ADRB1 4117/4885ADRA2C 4666/4885ALDH1A1 4848/4885 |
| US-20020025965-A1 | Antiserotonine agents | HTR2C, HTR3C, HTR3A | ADRB1 68/4885ADRA2C 25/4885ALDH1A1 3386/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | ADRB1 4005/4885ADRA2C 4715/4885ALDH1A1 1311/4885 |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | ADRB1 330/4885ADRA2C 1112/4885ALDH1A1 1599/4885 |
| US-20220411383-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | PIK3R5, PIK3CD, PIK3CG | ADRB1 1405/4885ADRA2C 2385/4885ALDH1A1 3446/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | ADRB1 4127/4885ADRA2C 4625/4885ALDH1A1 4834/4885 |
| US-20040224993-A1 | Diphenylurea compounds | HTR2C, HTR2A, HTR1A | ADRB1 63/4885ADRA2C 19/4885ALDH1A1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.